课题基金 / 基金详情

ORAL GANCICLOVIR TO PREVENT PROGRESSIVE CMV

ORAL GANCICLOVIR TO PREVENT PROGRESSIVE CMV
口服更昔洛韦预防进行性 CMV
批准号：
6280824
负责人：
ANN PETRU
金额：
$2.39万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6280824
关键词：
Herpesviridae disease chemoprevention clinical research clinical trials cytomegalovirus dosage ganciclovir human subject human therapy evaluation microorganism disease chemotherapy oral administration pediatric AIDS pharmacokinetics

项目摘要

项目成果

ANN PETRU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cytomegalovirus disease in children with HIV can progress and cause serious morbidity, especially as their immune system becomes more compromised, leading to eye, GI, and pulmonary complications. Many children become infected with CMV early, yet the disease remains quiescent until the CD4 counts drop. This study will evaluate the pharmacokinetics, maximum tolerated dose, longterm safety and tolerance, and the effect on CMV virology or oral ganciclovir.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LATE OUTCOMES FOR TREATMENT OF HIV INFECTION
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN CHILDRENPACTG 1010
ACTG P1024
ACTG P1024 EVALUATION OF THE IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE VACCINE...
海外基金